Over the past few years, Medtronic (NYSE: MDT) has faced significant challenges, including a pandemic-induced slowdown, relatively slow revenue growth, and economic issues that impacted its ...

Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps ...

The U.S. commercial rollout enabling its use with the MiniMed 780G pump is slated for this fall. Meanwhile, last November, Medtronic secured a clearance for its smart insulin pen app, designed for ...

Upgrading Medtronic to 'Strong Buy' with a $104 fair ... The Diabetes business manufactures insulin pumps, sensors, continuous glucose monitoring (CGM) system and infusion sets for the management ...

A Micra AV pacemaker is on display. (Photo by Tang Yanjun/China News Service via Getty Images) Medtronic (NYSE:MDT) is scheduled to announce its earnings on Wednesday, May 21, 2025. Over the last ...

Global medical device company Medtronic announced Wednesday that it intends to separate its diabetes business into a standalone company. The new diabetes company will focus on accelerating ...

I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations ... The growth was broad-based with strength in pump CGM and consumables. We continue to grow our MiniMed 780G ...

GALWAY, Ireland – Medtronic has announced it intends to separate its diabetes business, which represented 8% of revenue and 4% of segment operating profit in fiscal year 2025, into a new standalone ...

Explore Medtronic stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for MDT.